FDA Corrects Withdrawal of 72 ANDAs: What Manufacturers Must Know

Last updated: 2026-04-09

A Federal Register correction notice published on March 26, 2026 has brought renewed attention to one of the more significant regulatory actions of 2025: the FDA's withdrawal of approval of 72 Abbreviated New Drug Applications (ANDAs) from multiple applicants, originally announced on September 24, 2025 (90 FR 183, page 45942, FR Doc. 2025-18453). The correction — published at 2026-05913 — clarifies specific applicant and product details within that original notice, including an error related to ANDA 070631 for valproic acid capsules (250 mg) held by Upsher-Smith Laboratories, LLC.

For quality and regulatory professionals operating in the pharmaceutical and medical device space, this notice is more than a clerical fix. It is a signal — one that carries real implications for your quality management system (QMS), supplier qualification programs, and ongoing product portfolio risk assessments.

Let me break down what happened, what it means, and what you should be doing about it right now.

What the FDA's Correction Notice Actually Says

The original September 24, 2025 notice announced that, effective October 23, 2025, the FDA was withdrawing approval of 72 ANDAs submitted by Elite Laboratories, Inc. and other named applicants. ANDA withdrawals at this scale are uncommon and reflect a combination of voluntary withdrawals (often initiated by the applicant when a product is no longer commercially viable) and FDA-initiated withdrawals tied to compliance or safety concerns.

The March 2026 correction specifically addresses inaccuracies in the original document — including details surrounding ANDA 070631 for valproic acid, capsule, 250 milligrams, previously attributed to Upsher-Smith Laboratories, LLC. Correction notices of this type, while procedurally routine for the Federal Register, carry compliance weight: they update the official regulatory record, and any organization that relied on the original notice for supplier qualification, formulary management, or sourcing decisions must update their documentation accordingly.

Citation hook: The FDA's withdrawal of approval of 72 ANDAs, effective October 23, 2025, represents one of the largest single-notice ANDA withdrawal actions published in the Federal Register in recent years, affecting multiple applicants across a range of generic drug products.

Why ANDA Withdrawals Happen — And Why Scale Matters

Before diving into what this means for your business, it's worth understanding the mechanics of ANDA withdrawal.

Voluntary vs. FDA-Initiated Withdrawals

The sheer volume of 72 ANDAs in a single notice suggests that a significant portion of these are voluntary withdrawals — applicants cleaning house on products that are no longer manufactured or commercially distributed. This is actually a mechanism the FDA encourages; maintaining approvals for products not in active production creates regulatory burden without safety benefit.

However, regardless of the reason for withdrawal, the regulatory consequence is the same: those ANDAs no longer carry FDA approval, and any entity that manufactures, distributes, references, or relies upon those applications in their supply chain must treat them accordingly.

Citation hook: Under 21 CFR § 314.150, an ANDA withdrawal — whether voluntary or FDA-initiated — immediately invalidates the approved status of the application, requiring all downstream commercial and compliance reliances on that approval to be reassessed.

The Elite Laboratories Connection: Context and History

Elite Laboratories, Inc., named as the lead respondent in the original notice's title, is a New Jersey-based generic pharmaceutical manufacturer. The company has had a historically complex regulatory relationship with the FDA, including periods of intensive scrutiny related to manufacturing quality and compliance. Elite has also been involved in specialty drug development, including abuse-deterrent formulations.

The naming of Elite Laboratories, Inc. as the primary named entity in this withdrawal notice — alongside multiple co-applicants — is consistent with the FDA's practice of consolidating ANDA withdrawal actions into omnibus notices, particularly when a single applicant accounts for a substantial portion of the affected applications.

For industry observers, this is a reminder that regulatory history follows a company. When evaluating suppliers, contract manufacturers, or partners who have ANDAs in their portfolio, reviewing their Federal Register history — including withdrawal notices — is a basic element of due diligence.

What This Means for Your Quality Management System

Here is where I want to speak directly to quality and regulatory professionals reading this. Whether you are operating under ISO 13485:2016 for medical devices, 21 CFR Part 820 (Quality System Regulation), or 21 CFR Parts 210/211 (cGMP for pharmaceuticals), the implications of this notice touch several core QMS functions.

1. Supplier Qualification and Re-Qualification

If any of the 72 withdrawn ANDAs are held by organizations in your approved supplier list (ASL), your supplier qualification records are now out of date. ISO 13485:2016 clause 7.4.1 requires that you evaluate and select suppliers based on their ability to meet requirements — and an organization whose ANDAs have been withdrawn (particularly for compliance reasons) may no longer meet your qualification criteria.

Action required: - Cross-reference your ASL against the full list of affected ANDAs in FR Doc. 2025-18453 and its March 2026 correction. - Document your review in your supplier qualification records, even if no affected suppliers are identified. A documented "no impact" finding is still a finding — and auditors will look for it. - If affected suppliers are identified, initiate a formal supplier re-evaluation per your documented procedure.

2. Raw Material and Component Sourcing

For pharmaceutical manufacturers who source API (active pharmaceutical ingredient) or finished dosage forms referencing any of the 72 ANDAs, those sourcing arrangements require immediate review. Continuing to purchase or use materials whose regulatory basis has been withdrawn creates adulteration risk under 21 CFR § 501.

3. Product Portfolio and Formulary Risk Assessment

Hospitals, pharmacy benefit managers, and specialty distributors should flag any product in their formularies that was manufactured under one of the withdrawn ANDAs. The withdrawal effective date of October 23, 2025 means that any product commercially distributed after that date under a withdrawn ANDA would be considered unapproved — a significant regulatory and liability exposure.

4. Document Control: The Correction Notice Matters

The March 2026 correction notice is not optional reading. It is the controlling regulatory document for the specific ANDAs and applicants it corrects. If your organization's regulatory file references the original September 2025 notice, it must be updated to reflect the correction. Under both ISO 13485:2016 clause 4.2.4 and 21 CFR Part 820.40, document control requires that superseded documents be clearly identified and current versions maintained.

Citation hook: A Federal Register correction notice carries the same legal and regulatory authority as the original document it amends; organizations that fail to update their compliance records to reflect published corrections assume the risk of operating on superseded regulatory information.

The Valproic Acid Detail: Why Specific Product Corrections Matter

The specific correction relating to ANDA 070631 — valproic acid, capsule, 250 mg — and its attribution to Upsher-Smith Laboratories, LLC deserves particular attention.

Valproic acid is a narrow therapeutic index (NTI) drug used primarily for epilepsy and bipolar disorder. NTI drugs are subject to heightened regulatory scrutiny because small variations in bioavailability can have significant clinical consequences. The FDA has historically applied more rigorous standards to generic NTI drugs, including more stringent bioequivalence requirements.

For any organization — whether a hospital system, pharmacy chain, specialty distributor, or contract manufacturer — that has valproic acid products in scope, this correction is a trigger for a formal regulatory impact assessment. The question is not simply whether this particular ANDA affects your operations; the question is whether your existing processes would have caught this correction without someone manually monitoring the Federal Register.

If the answer is no, you have a process gap.

Industry Statistics: The Scale of ANDA Activity in the U.S.

To appreciate the significance of this withdrawal action, consider the broader context of ANDA activity:

• As of 2024, the FDA's Office of Generic Drugs (OGD) had over 90,000 approved ANDAs in its active inventory, representing the backbone of the U.S. generic drug market, which accounts for approximately 90% of all prescriptions dispensed in the United States (FDA OGD Annual Report 2024).
• The FDA received approximately 1,200 original ANDA submissions in fiscal year 2024, while processing a comparable volume of approval, withdrawal, and tentative approval actions.
• Generic drugs save the U.S. healthcare system an estimated $373 billion annually (Association for Accessible Medicines, 2023 Generic Drug & Biosimilars Access & Savings Report), making the integrity of the ANDA approval system a public health issue — not merely a regulatory one.
• Studies of FDA ANDA withdrawal patterns indicate that voluntary withdrawals account for the majority (approximately 70-80%) of ANDA withdrawals in any given year, with compliance-based withdrawals representing a smaller but more consequential subset.

How Certify Consulting Approaches Regulatory Monitoring for Clients

At Certify Consulting, one of the most consistent gaps I see when onboarding new clients is the absence of a proactive regulatory intelligence process. Most organizations have a procedure for responding to regulatory changes — but very few have a systematic process for identifying those changes before they create a compliance problem.

A Federal Register correction notice like this one is a perfect example. It is not a press release. It does not generate media coverage. It is published in a 300-page government document that most quality teams are not reading on a weekly basis. And yet, for organizations with affected products or suppliers, it carries real compliance obligations.

Here is the framework I recommend:

Regulatory Monitoring Framework for ANDA-Adjacent Organizations

This framework integrates naturally with your existing ISO 13485 internal audit program and should be reflected in your Management Review inputs under ISO 13485:2016 clause 5.6.2.

What You Should Do This Week

If you are a quality, regulatory, or operations professional in the pharmaceutical or medical device space, here is your action checklist following this correction notice:

1. Pull the correction notice from the Federal Register (Document 2026-05913, March 26, 2026) and file it alongside FR Doc. 2025-18453 in your regulatory reference library.
2. Run a cross-reference of the 72 affected ANDAs against your approved supplier list, product portfolio, and any formulary or sourcing agreements.
3. Document your review — even a "no impact" determination must be recorded with a date, reviewer name, and methodology.
4. Update your supplier qualification records for any supplier with a direct or indirect connection to the affected ANDAs.
5. Assess your regulatory monitoring process — if this correction notice was not on your radar until now, that is the real finding.
6. Brief your management team — ANDA withdrawal actions at this scale are a legitimate Management Review agenda item under clause 5.6.2.

Expert Analysis: The Broader Signal for Quality Professionals

I have spent over eight years working with 200+ clients across pharmaceutical, medical device, and combination product organizations. One pattern I see repeatedly is that organizations treat regulatory notices as someone else's problem until they are suddenly, urgently, their problem.

The FDA's withdrawal of 72 ANDAs — and subsequent correction of that withdrawal notice — is a reminder that the regulatory environment is dynamic, and that quality systems must be designed to absorb regulatory change, not merely react to it. The organizations that pass their first-time audits (and we maintain a 100% first-time pass rate at Certify Consulting precisely because of this philosophy) are those that have institutionalized regulatory awareness as a QMS function, not an afterthought.

If your organization needs help building or strengthening that regulatory intelligence capability — or if you need a gap assessment against ISO 13485:2016, 21 CFR Part 820, or 21 CFR Parts 210/211 — I encourage you to visit certify.consulting to learn more about how we work with clients across the product lifecycle.

For more on how regulatory changes integrate with your quality management system, see our related guide on ISO 13485 management review requirements.

Last updated: 2026-04-09

Source: Federal Register, Document 2026-05913, March 26, 2026. Available at: https://www.federalregister.gov/documents/2026/03/26/2026-05913/elite-laboratories-inc-et-al-withdrawal-of-approval-of-72-abbreviated-new-drug-applications

Frequently Asked Questions

What does it mean when the FDA withdraws an ANDA?

When the FDA withdraws approval of an Abbreviated New Drug Application (ANDA), the generic drug product covered by that application is no longer legally approved for commercial marketing in the United States. Manufacturers, distributors, and other supply chain participants must cease relying on that approval for commercial or regulatory purposes.

Does a Federal Register correction change the effective date of the original withdrawal?

No. A correction notice updates specific factual details (such as applicant names, ANDA numbers, or product descriptions) within the original notice. The effective date of the underlying action — in this case, October 23, 2025 — remains unchanged unless the correction explicitly states otherwise.

How does this ANDA withdrawal affect ISO 13485-certified organizations?

ISO 13485-certified organizations that source components, materials, or finished goods from suppliers with affected ANDAs must update their supplier qualification records under clause 7.4.1. Additionally, the correction notice itself must be incorporated into document control processes per clause 4.2.4, and the regulatory development may warrant inclusion as a Management Review input under clause 5.6.2.

Why was valproic acid specifically called out in the correction?

The correction addressed an error in the original September 2025 notice regarding ANDA 070631 for valproic acid capsules, 250 mg, and its attribution to Upsher-Smith Laboratories, LLC. Valproic acid is a narrow therapeutic index drug, which means regulatory accuracy in its ANDA records is particularly important given the clinical sensitivity of product sourcing decisions for this drug class.

What is the best way to monitor FDA ANDA withdrawal notices proactively?

Organizations should subscribe to FDA RSS feeds and Federal Register email alerts filtered for FDA Drug notices, maintain a documented regulatory monitoring procedure, and assign a responsible function — typically Regulatory Affairs or Quality Assurance — to review and route relevant notices on a defined frequency (weekly is recommended for high-risk supply chains).